


















![]()
Q1: 2026-05-07 Earnings Summary
EPS of -$0.29 misses by $0.00
|
Revenue of
$15.47M
(-24.91% Y/Y)
beats by $370.00K
Personalis, Inc. (PSNL) Q1 2026 Earnings Call May 7, 2026 5:00 PM EDT
Company Participants
Christopher Hall - CEO & Director
Aaron Tachibana - CFO & COO
Richard Chen - Executive VP of R&D, President & Chief Medical Officer
Conference Call Participants
Caroline Corner - Westwicke Partners, LLC
Subbu Nambi
Mark Massaro - BTIG, LLC, Research Division
Thomas Flaten - Lake Street Capital Markets, LLC, Research Division
Joseph Conway - Needham & Company, LLC, Research Division
Daniel Brennan
William Bonello - Craig-Hallum Capital Group LLC, Research Division
Presentation
Operator
Greetings, and welcome to the Personalis First Quarter 2026 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded.
It is now my pleasure to introduce Caroline Corner of Investor Relations. Thank you, and you may proceed, Caroline.
Caroline Corner
Westwicke Partners, LLC
Thank you, operator. Welcome to Personalis' First Quarter 2026 Earnings Call. Joining today's call are Chris Hall, Chief Executive Officer; Aaron Tachibana, Chief Financial and Chief Operating Officer; and Rich Chen, President and Chief Medical Officer.
All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements within the meaning of the U.S. securities laws, including any statements regarding trends and expectations for our financial performance this year and longer term, cash runway and liquidity position, revenue expectations and timing, size and booking of orders, products, services, technology, expansion of clinical volume, reimbursement goals, the outcome and timing of reimbursement decisions, expectations for our existing and future collaboration activities, cost expectations, market size and our market opportunity and business outlook.
These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. We encourage you to review our recent filings, including the risk factors described in our most recent filings. Personalis undertakes no obligation to update these
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。